Swiss Single Registration Number – CHRN
The Swiss Single Registration Number (CHRN) is assigned by Swissmedic based on the Medical Device Ordinance (MedDO; SR 812.213). It is assigned to Swiss manufacturers, authorised representatives or importers and serves to uniquely identify them.
Meditrial successfully represents many global life sciences companies as their Swiss Representative.
Until the MRA (Mutual Recognition Agreement) is updated, Swissmedic is unable to assign a European Single Registration Number (SRN) via EUDAMED for Swiss economic operators. In order to mitigate this loss of information and to further ensure market surveillance in Switzerland, manufacturers, authorised representatives and importers established in Switzerland must register once with Swissmedic.
Economic operators must register within three months of launching their first product on the Swiss market. The timeframe is intended to avoid delays in the launch of compliant products and to prevent supply bottlenecks in Switzerland. For subsequent product launches, no further registration is required.
Swissmedic has published an information sheet which describes in detail the process of applying for a CHRN. Visit the Swissmedic website for more details.
Using the industry’s best practices and high-end expertise, Meditrial’s specialized team offers Swiss Rep services and regulatory support for compliance with the Swiss Regulations and applicable requirements.
Trust us to keep market access in Switzerland for your device.
Get in touch today!
Table of Contents
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
The contribution of patient associations in clinical trials
Historically, patient organizations have had the primary purpose of supporting the communities they represented. Today, this remains a crucial function, but modes have changed, as has the role that associations and patients themselves take on [...]
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
